A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer

Trial Profile

A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Robatumumab (Primary) ; Antineoplastics
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top